Pharmacopeia

CWP-0098

FENTANYL

Neurology & Sedation · Level 1

Core pharmacology

Class Group

Opiate Analgesic

Introduction

Tertiary amine which is a synthetic phenylpiperidine derivative

Indications Uses

1. to provide the analgesic component in general anaesthesia
2. in combination with a major tranquillizer to produce neuroleptanalgesia
3. to provide analgesia during labour when regional anaesthesia is not in
use
4. as an agent used for patient-controlled analgesia
5. in premedication and
6. for palliative care

Presentation

colourless solution 50mcg/ml, TDpatch (25mcg-100mcg/hr) and as lozenges

Main Action

μ receptor agonist

Mechanism of action

Binds primarily to inhibitory G-protein-coupled μ-opioid receptors → inhibits adenylyl cyclase → ↓ cAMP → opens K+ channels and inhibits presynaptic voltage-gated Ca2+ channels → hyperpolarisation and ↓ neurotransmitter release

Physiological effects

inhibitory action,
modulating the pain response to produce analgesia.

less likely to ppt histamine release
norad& serotonin axn, excitatory centrally

Absorption

IV/IM/TD. BA PO 30%SL50%skin>90%
onset IM.: 7-8 mins; IV imm; TD 6 hrs
duration IM:1-2 hrs; IV:0.5-1hr; TD 12hrs

Distribution

relative lipid sol 500

Rapid redistribution
pKa 8.4(10% union)

Protein binding

prot bind 80-85%

Volume of distribution

Mod Vd 4-6L/kg

Metabolism

Slow Hepatic, primarily via CYP3A4clearance

Excretion

excretion Urine 75%

Half-life

half life I.V.: 2-4 hours, prolonged context sensitive half time

Special Points

- Incompatible with thiopental

- Dialysis - unknown

Route And Dose

Bolus: 1-2 mcg/kg
inf: 1-2 mcg/kg/hr

(relative potency 50-100)

Adverse Effects Toxicity

Respiratory depression including postoperative recurrence. Bradycardia. Chest-wall rigidity. Nausea and vomiting. Dependence. Decreased gastrointestinal motility.